RZL-012
Phase 2Small molecule
RZL-012 is one of 7 small molecule programs targeting Lipoma. It is currently in Phase 2.
1
Indications
9
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Lipoma
#DrugCompanyPhaseTrials
1Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xiaflex
GGrupo Espanol de Tumores Neuroendocrinos
Phase 2
Kybella
AbbViePhase 1
AA4500
Endo PharmaceuticalsPhase 2
Kybella
AbbViePhase 1
CBL-514
CCaliway Biopharmaceuticals Co., Ltd.
Phase 2
RZL-012
RRaziel Therapeutics Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Safety and Efficacy3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RZL-012. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRaziel Therapeutics Ltd.